Ozempic has become one of the most searched health topics in India. Whether you are a diabetic looking for better blood sugar control or someone exploring medical weight loss, the questions are the same — how much does Ozempic cost now, is it affordable, and should I take it?

As a practising diabetologist in Greater Noida with over 15 years of experience prescribing GLP-1 medications, here is my honest, evidence-based guide to everything you need to know about Ozempic in India in 2026 — updated for the April 1 price cut.

What Is Ozempic and How Does It Work?

Ozempic is the brand name for semaglutide, a once-weekly injectable medication made by Novo Nordisk. It belongs to a class called GLP-1 receptor agonists — drugs that mimic a gut hormone to regulate blood sugar, reduce appetite, and slow gastric emptying.

In simple terms, Ozempic helps your body release insulin when blood sugar is high, reduces the amount of sugar your liver produces, and makes you feel full faster — leading to lower blood sugar levels and meaningful weight loss.

Ozempic Price in India — April 2026 (New Reduced Prices)

Effective April 1, 2026, Novo Nordisk India has cut the price of Ozempic by up to 36% and Wegovy by up to 48% across dose strengths. This is the company's second price reduction in five months, and it brings branded semaglutide significantly closer to the price of newly launched generics.

Here are the current branded Ozempic prices after the cut:

Dose	Old Weekly Price	New Weekly Price	New Monthly Price
0.25 mg (starting dose)	₹2,200	₹1,415	₹5,660
0.5 mg (escalation)	₹2,542	~₹1,940	~₹7,760
1 mg (maintenance)	₹2,793	~₹2,125	~₹8,500

Prices reflect Novo Nordisk India's April 1, 2026 revision. The 0.25 mg dose saw the largest reduction (36%); the average reduction across all doses is approximately 23.8% for Ozempic and 27% for Wegovy. Exact MRPs may vary slightly between pharmacies. Verify at the time of purchase.

Wegovy has seen an even steeper cut — its 0.25 mg starting dose dropped from ₹10,848 to ₹5,660/month, a reduction of 48%.

Insurance currently does not cover Ozempic in India for most patients, so this remains an out-of-pocket cost. However, the combination of the April price cut and the availability of generics means GLP-1 therapy is now genuinely affordable for a far larger section of Indian patients than it was even six months ago.

What the April Price Cut Means for Patients — A Clinical View

Let me be direct about what I am telling my patients at Nirvana Clinic since the April 1 announcement:

1. The price cut is welcome, but generics are still cheaper

Even after the April 1 reduction, branded Ozempic at ₹5,660/month for the starting dose remains more expensive than generic semaglutide alternatives. Generic vials from Natco Pharma (Semanat), Glenmark (GLIPIQ), and Eris Lifesciences (Sundae) start from ₹1,290–₹1,800/month. Generic pens from Dr. Reddy's (Obeda) and Alkem (Semasize) cost ₹1,800–₹4,500/month. For a cost-conscious patient, generics remain the most affordable route — and the molecule is clinically identical. I have covered this in detail in my complete guide to generic semaglutide in India.

2. For patients who prefer the innovator brand, the gap has narrowed

Some patients — particularly those who value Novo Nordisk's 49 million patient-years of global safety data, established cold-chain infrastructure, and reliable pen device quality — are willing to pay a premium for the branded product. Before April 1, that premium was very large (₹8,800 vs ₹1,290 = 6.8× more expensive). After April 1, it is roughly 4.4× more expensive. Still significant, but meaningfully closer.

3. More patients can now start GLP-1 therapy earlier

The most important clinical impact of this price cut is that eligible patients can now begin treatment sooner, when their diabetes is milder, their weight is lower, and the chance of diabetes reversal is highest. I have already seen patients this month who delayed starting GLP-1 therapy for over a year purely due to cost and are now ready to begin.

4. Rybelsus (oral semaglutide) pricing has NOT changed

Novo Nordisk has confirmed that the April 1 price cut applies only to injectable semaglutide (Ozempic and Wegovy). Rybelsus, the daily oral tablet form of semaglutide, remains at its previous price. For patients who specifically want tablet-based therapy, this is an important detail to factor into your decision.

Generic Semaglutide in India — The Background

Novo Nordisk's Indian semaglutide patent expired on March 20, 2026. Within days, Indian pharmaceutical companies launched their own versions at dramatically lower prices. This — not brand loyalty — is what forced Novo's April 1 price cut.

As of April 2026, more than 40 DCGI-approved generic semaglutide brands are now in circulation across India, including:

• Natco Pharma — Semanat (vials from ₹1,290/month)
• Sun Pharma — Sematrinity for diabetes (₹3,000–₹5,200/month); Noveltreat for weight loss (₹3,600–₹8,000/month)
• Dr. Reddy's Laboratories — Obeda pen (₹4,200/month)
• Alkem — Semasize pen (from ₹1,800/month)
• Glenmark — GLIPIQ
• Zydus Lifesciences, Torrent Pharmaceuticals, Eris Lifesciences, Lupin, Cipla — multiple brands launching

All of these contain the identical semaglutide molecule as branded Ozempic. The differences are in delivery device (vial vs pre-filled pen), manufacturer, and price. For a detailed clinical breakdown of each generic brand, see my Generic Semaglutide India 2026 price guide.

Novo Nordisk is also launching second brands through partnerships — Extensior (Ozempic through Abbott India) and Poviztra (Wegovy through Emcure) — to compete with the generics wave through wider distribution.

Ozempic vs Mounjaro vs Rybelsus — Which Is Right for You?

Feature	Ozempic	Mounjaro	Rybelsus
Molecule	Semaglutide	Tirzepatide	Semaglutide
Route	Weekly injection	Weekly injection	Daily tablet
Mechanism	GLP-1 only	GIP + GLP-1 (dual)	GLP-1 only
Avg. weight loss	10–15%	15–22%	5–10%
HbA1c reduction	1.5–2%	2–2.5%	1–1.5%
Cost/month (Apr 2026)	₹5,660–₹8,500 (branded, new price) ₹1,290–₹4,500 (generic)	₹14,000–₹25,781	₹3,000–₹5,000
Best for	Diabetes + moderate weight loss	Maximum weight loss + diabetes	Patients who prefer tablets

At Nirvana Clinic, I prescribe all of these medications based on each patient's metabolic profile, budget, and treatment goals. There is no single "best" drug — the right choice depends entirely on your individual situation. Read more about our medical weight loss programme.

Who Should Take Ozempic? — Medical Eligibility

Ozempic is not a casual weight loss pill. It is a prescription medication that requires proper medical evaluation. You may be a candidate if:

• Type 2 diabetes not adequately controlled with metformin or other oral medications
• BMI over 30 (clinical obesity) with or without diabetes
• BMI over 27 with comorbidities like hypertension, sleep apnoea, or insulin resistance
• PCOS-related metabolic weight gain that has not responded to lifestyle changes alone
• Persistent insulin resistance despite a structured diet and exercise plan

Common Side Effects — What to Expect

Most side effects occur during the first 2–4 weeks as your body adjusts to the medication:

• Nausea — the most common side effect, usually mild and temporary
• Vomiting and diarrhoea — typically resolves within the first few weeks
• Constipation — can be managed with diet and hydration
• Abdominal discomfort — eating smaller, lighter meals helps
• Reduced appetite — this is the therapeutic effect, but extreme loss of appetite should be reported

Serious but rare risks include pancreatitis and gallbladder issues. This is precisely why GLP-1 medications should only be used under the supervision of a trained physician who monitors kidney function, pancreatic health, and nutritional status throughout the treatment. At Nirvana Clinic, I conduct regular blood work and follow-up consultations to ensure safe, sustainable results.

The Danger of Self-Medicating with "Weight Loss Pens"

With the surge of interest in GLP-1 drugs — amplified by the April 2026 price cut and the flood of affordable generics — social media is now full of people buying semaglutide pens online without prescriptions. This is dangerous for several reasons:

• Incorrect dosing can cause severe nausea, dehydration, and electrolyte imbalance
• Without baseline blood tests, underlying conditions (thyroid, pancreatic, kidney) may be missed
• Unmonitored use can lead to excessive muscle loss instead of fat loss
• Counterfeit products are increasingly common — with 50+ brands on the market, verification is critical
• Starting at the wrong dose (e.g., 1 mg instead of 0.25 mg) is a recipe for intolerable side effects and dropping out of therapy entirely

As a physician, I have seen patients who started self-medicating and developed complications that could have been easily prevented with proper medical oversight. The cost of a consultation is a fraction of the cost of managing complications — and far less than the cost of the drug itself, branded or generic.

What Makes Dr. Manuj Sondhi's Approach Different?

At Nirvana Clinic, Greater Noida, I take a "Metabolic First" approach to GLP-1 prescribing:

• Comprehensive metabolic workup before prescribing — including HbA1c, fasting insulin, lipid profile, kidney and liver function, thyroid panel
• Honest conversation about branded vs generic — I help patients choose the right option for their budget, not push a premium brand when a generic works equally well
• Personalised dose escalation — starting low and increasing only as needed, minimising side effects
• Nutritional monitoring — ensuring you lose fat, not muscle mass
• Regular follow-ups — blood work at 4, 8, and 12 weeks to track progress safely
• Combined approach — integrating medication with lifestyle changes, not replacing them

Read more about our comprehensive diabetes care programme and diabetes reversal approach.

Frequently Asked Questions